Pneumococcal Disease
📧 Sign up to get email alerts when something new happens for Pneumococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years. [Phase 2]
Phase 2 clinical trial update for a pneumococcal conjugate vaccine tested in adults aged 50 to 84; results have been posted.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults [Phase 1]
Pfizer conducted a Phase 1 trial to evaluate a pneumococcal vaccine that includes a novel ingredient (PF-07872411) intended to enhance vacci…
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) [Phase 3]
Phase 3 STRIDE-7 trial results report safety and immunogenicity data for the V116 pneumococcal vaccine in adults living with HIV, with resul…
-
CLINICAL_TRIALS trial_result · 2024-05-30Clinical Trial Update: Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) [Phase 3]
Phase 3 STRIDE-9 trial data show safety and immunogenicity of V116 in vaccine-naïve Japanese older adults for pneumococcal disease; results …
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) [Phase 3]
Merck's pneumococcal vaccine V116 completed a Phase 3 trial (STRIDE-4) in adults 18 to 49 years, assessing safety, tolerability, immunogenic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) [Phase 3]
A Phase 3 trial (STRIDE-6) evaluating the safety, tolerability, and immunogenicity of the V116 pneumococcal vaccine in adults with prior pne…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India [Phase 4]
A Phase 4 safety study evaluating the 13-valent pneumococcal conjugate vaccine (Prevnar 13) in healthy adults aged 18-49 in India; results w…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults [Phase 1, Phase 2]
Phase 1/2 trial update on the safety, tolerability, and immunogenicity of the 24-valent pneumococcal conjugate vaccine VAX-24 in adults; stu…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age [Phase 1]
Phase 1 clinical trial assessing safety and immunogenicity of pneumococcal conjugate formulations in healthy adults aged 18-49; results post…
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) [Phase 3]
Phase 3 trial update reporting safety and immunogenicity data for the 15-valent pneumococcal conjugate vaccine V114 in healthy infants in So…
-
CLINICAL_TRIALS trial_result · 2023-12-21Clinical Trial Update: A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine [Phase 1, Phase 2]
A phase 1/2 clinical trial update for ASP3772, a pneumococcal vaccine, including single ascending dose studies in adults and elderly subject…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants [Phase 3]
A Phase 3 trial evaluating safety and immunogenicity of a 4-dose series of a 20-valent pneumococcal conjugate vaccine in healthy infants has…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan [Phase 3]
Phase 3 trial evaluating safety and immunogenicity of the 20-valent pneumococcal conjugate vaccine in adults 60+ who have not previously rec…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People [Phase 3]
A Phase 3 study is recruiting to evaluate immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy adults.
-
CLINICAL_TRIALS trial_result · 2023-06-13Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants [Phase 3]
Phase 3 safety study of the 20-valent pneumococcal conjugate vaccine in healthy infants completed with results posted.
-
EMA approval · 2023-05-24EMA Authorised: Synflorix (Pneumococcal polysaccharide serotype 23F;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19F) — GlaxoSmithKline Biologicals S.A.
EMA has authorised Synflorix, a pneumococcal conjugate vaccine by GlaxoSmithKline Biologicals S.A., for immunization against multiple pneumo…
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants [Phase 3]
Phase 3 trial evaluating safety and immunogenicity of a 3-dose series of a 20-valent pneumococcal conjugate vaccine in healthy infants; resu…
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age [Phase 3]
Phase 3 safety and immunogenicity study of 20vPnC in healthy children aged 15 months to 17 years completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants [Phase 3]
Phase 3 trial assessing safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants; results posted af…
-
CLINICAL_TRIALS trial_result · 2023-02-10Clinical Trial Update: Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil. [Phase 3]
Phase 3 trial evaluating non-inferiority of a 12-valent pneumococcal conjugate vaccine in healthy Brazilian children.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) [Phase 4]
Phase 4 trial update on preventing pneumococcal disease through vaccination (Study 2).
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 [Phase 3]
Phase 3 safety and immunogenicity study evaluating coadministration of 20vPnC with a booster dose of BNT162b2; completed with results posted…
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam [Phase 2, Phase 3]
A completed Phase 2/Phase 3 clinical trial evaluating pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam.
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age [Phase 3]
Phase 3 trial assessing safety and immunogenicity of 20vPnC given with SIIV in adults aged 65 and older; study completed with results posted…
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 [Phase 4]
Phase 4 trial evaluating safety and immunogenicity of combined immunization with a COVID-19 inactivated vaccine alongside quadrivalent influ…